Article

Besifloxacin ophthalmic suspension gains additional indications

The FDA has granted additional labeling indications for besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch + Lomb).

Madison, NJ-The FDA has granted additional labeling indications for besifloxacin ophthalmic suspension 0.6% (Besivance), according to Bausch + Lomb, the solution’s manufacturer.

The indications now include treating bacterial conjunctivitis infections caused by susceptible isolates of Pseudomonas aeruginosa, a rare but potentially virulent pathogen that can be associated with serious eye conditions, such as corneal ulcers and blindness. Three other significant ocular pathogens added to the indications granted for the eye drop include Aerococcus viridans, Moraxella catarrhalis, and Staphylococcus warneri.

Besivance suspension has been approved in the United States for the treatment of bacterial conjunctivitis since 2009 and has demonstrated potent activity and high rates of eradication against problematic multi-drug resistant gram-positive organisms.

“Many eye-care physicians consider Pseudomonas aeruginosa as a more serious threat to ocular health than MRSA,” said Terrence P. O’Brien, MD, of the Bascom Palmer Eye Institute of the University of Miami, FL. “With the additional indication of Pseudomonas aeruginosa as well as the other important ocular pathogens covered by besifloxacin 0.6%, physicians now have a potent, broad-spectrum, branded prescription eye drop to . . . treat bacterial conjunctivitis caused by the most common serious sight-threatening pathogens.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.